StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $19.91 | $19.04 | -4.35% | 0.6M |
| 05-12 | $18.95 | $18.63 | -1.69% | 0.6M |
| 05-13 | $18.51 | $18.15 | -1.94% | 0.7M |
| 05-14 | $18.25 | $18.88 | +3.45% | 0.7M |
| 05-15 | $18.69 | $19.13 | +2.35% | 0.6M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $83.68M | $344.23M | $257.22M | $174.18M |
Operating Income | $-18.41M | $-42.81M | $-38.98M | $-32.18M |
Net Income | $-14.52M | $-24.16M | $-21.83M | $4.52M |
EPS (Diluted) | $-0.49 | $-0.83 | $-0.76 | $-0.74 |
Total Assets | $547.80M | $578.56M | $562.79M | $544.73M |
Total Liabilities | $86.39M | $107.68M | $95.74M | $89.35M |
Cash & Equivalents | $63.76M | $116.73M | $85.56M | $82.23M |
Free Cash Flow OCF − CapEx | $-34.58M | $28.33M | $8.58M | $782.00K |
Shares Outstanding | 30.30M | 29.69M | 29.16M | 28.98M |
No sell-side coverage available for CSTL.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for CSTL.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.